The protocol longevity researchers actually follow. AMPK activation, NAD+ restoration, sirtuin activation, and systemic inflammation reduction — four mechanistically distinct pathways targeting biological aging.
arq Longevity is the healthspan optimization pack inspired by longevity research (Peter Attia-adapted for India). It combines metformin (AMPK activation), NMN (NAD+ restoration), rapamycin (if indicated), and comprehensive biomarker tracking to target four distinct aging pathways: metabolic efficiency, cellular energy, sirtuin activation, and systemic inflammation reduction.
arq Longevity targets the four fundamental hallmarks of biological aging: mitochondrial dysfunction, NAD+ depletion, genomic instability, and systemic inflammation. Each component addresses a distinct mechanism recognized in leading longevity research.
| Component | Dosage | Mechanism | Monitoring |
|---|---|---|---|
| Metformin ER | 500mg BID | AMPK activation, metabolic health | Glucose, HbA1c, kidney function |
| NMN | 500mg daily | NAD+ restoration, mitochondrial function | Cellular NAD+ levels, energy markers |
| Resveratrol | 500mg daily | Sirtuin activation, inflammation reduction | Inflammatory markers (CRP, IL-6) |
| Omega-3 (EPA/DHA) | 1000mg daily | Systemic inflammation, cardiovascular health | Omega-3 index, lipid panel |
Metformin activates AMPK, the cellular energy sensor. NMN restores NAD+ that AMPK and sirtuins require as cofactors. Resveratrol directly activates SIRT1, the master longevity gene. Omega-3 reduces the systemic inflammation that accelerates aging across all tissues. Together, these four molecules address the four pillars of longevity research: metabolic health, NAD+ restoration, genetic integrity, and inflammatory suppression.
Longevity pharmacology requires sustained NAD+ elevation, mTOR suppression, and antioxidant defense. This stack targets three aging pathways: metabolic dysfunction, cellular senescence, and mitochondrial decline.
| Metformin | Tmax 2.5h, t½ 6.2h, ~50–60% bioavail, renal excretion |
| NMN | Tmax 0.5–1h, t½ ~3h, bioavail better sublingual, converts to NAD+ |
| Rapamycin | Tmax 1–3h, t½ 62h (!), ~14% bioavail, CYP3A4, weekly dosing |
| Resveratrol | Tmax 0.5–1.5h, t½ 1–3h, <1% oral bioavail (!), glucuronidated |
| Key note | Rapamycin 5mg weekly is LONGEVITY dose, not immunosuppressive dose |
| NAD+ peak | NMN + metformin: 60–90 min post-dose. Rapamycin: 24–48h post-dose |
This is a longevity-focused protocol designed for long-term adherence. Consistency and adherence matter more than exact timing. Rapamycin dosing is unique: weekly, not daily.
Each component addresses a distinct mechanism of aging. Together, they create a multi-pathway longevity protocol supported by mechanistic and clinical evidence.
At longevity doses, this stack has an excellent safety profile. Metformin GI effects improve over 2–4 weeks. Rapamycin at 5mg weekly is far safer than immunosuppressive doses (5–20mg daily).
Rapamycin is the primary driver of interactions in this stack (CYP3A4 substrate). Metformin has minimal metabolism. Resveratrol inhibits CYP3A4/2C9, potentially raising rapamycin levels.
Book a consultation with a licensed physician to discuss whether arq Longevity is appropriate for you.